Pricing Agreement, dated September 26, 2024, among the Company and Morgan Stanley & Co. LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein
Exhibit 1.2
PRICING AGREEMENT
September 26, 2024
Morgan Stanley & Co. LLC
BofA Securities, Inc.
Wells Fargo Securities, LLC
As Representatives of the several Underwriters named in Schedule I hereto
c/o Morgan Stanley & Co. LLC
1585 Broadway, 29th Floor
New York, New York 10036
United States of America
c/o BofA Securities, Inc.
One Bryant Park
New York, New York 10036
United States of America
c/o Wells Fargo Securities, LLC
550 South Tryon Street, 5th Floor
Charlotte, North Carolina 28202
Ladies and Gentlemen:
MetLife, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein (this “Agreement”) and in the Underwriting Agreement, dated September 26, 2024 (the “Underwriting Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) the principal amounts of its Securities specified in Schedule I hereto.
Each of the provisions of the Underwriting Agreement is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Agreement, the Applicable Time, and the Closing Date. Each reference to the Representatives herein and in the provisions of the Underwriting Agreement so incorporated by reference shall be deemed to refer to you. A reference to the Indenture shall be deemed to refer to the Indenture, dated as of November 9, 2001, between the Company and The Bank of New York Mellon Trust Company, N.A. (the “Trustee,” as successor to J.P. Morgan Trust Company, National Association (as successor to Bank One Trust Company, N.A.)), as supplemented by the Forty-Sixth Supplemental Indenture, dated as of June 5, 2024, and the Forty-Seventh Supplemental Indenture, to be dated as of September 30, 2024, in each case, between the Company and the Trustee. Unless otherwise defined herein, terms defined in the Underwriting Agreement are used herein as therein defined. The Representatives designated to act on behalf of the Underwriters of the Securities pursuant to the Underwriting Agreement are designated as the “Joint Book-Running Managers” at the end of Schedule II hereto.
Subject to the terms and conditions set forth herein and in the Underwriting Agreement incorporated herein by reference, at the time and at the purchase price to the Underwriters set forth in Schedule III hereto, the Company agrees to issue, sell and deliver to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the time and at the purchase price to the Underwriters set forth in Schedule III hereto, the principal amounts of Securities set forth opposite the name of such Underwriter in Schedule I hereto. The date of the issuance, sale and delivery of the Securities is the “Settlement Date” set forth on Schedule II hereto and such date shall be considered a Closing Date under the Underwriting Agreement.
If the foregoing is in accordance with your understanding, please sign and return to us counterparts hereof, and upon acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof, including the provisions of the Underwriting Agreement incorporated herein by reference, shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is or will be pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on the part of the Representatives as to the authority of the signers thereof.
[Signature pages follow]
2
| Very truly yours, | ||
| METLIFE, INC. | ||
| By: | /s/ John Hall | |
| Name: | John Hall | |
| Title: | Executive Vice President and | |
| Treasurer | ||
[Signature Page to Pricing Agreement]
Accepted as of the date hereof on behalf of each of the Underwriters:
| MORGAN STANLEY & CO. LLC | ||
| By: | /s/ Erica Mui | |
| Name: | Erica Mui | |
| Title: | Managing Director | |
[Signature Page to Pricing Agreement]
| BOFA SECURITIES, INC. | ||
| By: | /s/ Randolph B. Randolph | |
| Name: | Randolph Randolph | |
| Title: | Managing Director | |
[Signature Page to Pricing Agreement]
| WELLS FARGO SECURITIES, LLC | ||
| By: | /s/ Lucas Werner | |
| Name: | Lucas Werner | |
| Title: | Vice President | |
[Signature Page to Pricing Agreement]
SCHEDULE I
TO PRICING AGREEMENT
| Underwriters | Principal Amount of $250,000,000 5.300% Senior Notes due 2034 to be Purchased | |||
| Morgan Stanley & Co. LLC | $ | 175,000,000 | ||
| BofA Securities, Inc. | $ | 37,500,000 | ||
| Wells Fargo Securities, LLC | $ | 37,500,000 | ||
|
|
| |||
| Total | $ | 250,000,000 | ||
|
|
| |||
Schedule I - 1
SCHEDULE II
TO PRICING AGREEMENT
Filed pursuant to Rule 433
September 26, 2024
Relating to
Preliminary Prospectus Supplement dated September 26, 2024 to
Prospectus dated November 17, 2022
Registration Statement No. 333-268442
MetLife, Inc.
$250,000,000 5.300% Senior Notes due 2034 (the “Notes”)
Final Term Sheet
September 26, 2024
The information in this final term sheet relates to the offering of the securities specified herein and should be read together with the preliminary prospectus supplement dated September 26, 2024 (the “Preliminary Prospectus Supplement”), including the documents incorporated by reference therein, and the accompanying prospectus dated November 17, 2022, filed pursuant to Rule 424(b) under the Securities Act of 1933 (Registration Statement File No. 333-268442). This final term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement. Capitalized terms used but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus Supplement.
| Issuer: | MetLife, Inc. (“Issuer”) | |
| Securities: | 5.300% Senior Notes due 2034 | |
| Aggregate Principal Amount: | $250,000,000. The Notes offered hereby will be identical to the terms of, and will be part of the same series as, the $500,000,000 aggregate principal amount of the 5.300% Senior Notes due 2034 issued by the Issuer on June 5, 2024. Upon settlement, the outstanding aggregate principal amount of the 5.300% Senior Notes due 2034, including the Notes offered hereby, will be $750,000,000. | |
| Price to the Public: | 104.611% of principal amount, plus accrued interest of $4,232,639 from, and including, June 5, 2024 to, but excluding, the Settlement Date | |
| Gross Underwriting Discount: | 0.450% | |
| Net Proceeds to Issuer**: | $260,402,500, plus accrued interest of $4,232,639 from, and including, June 5, 2024 to, but excluding, the Settlement Date | |
Schedule II - 1
| Maturity Date: | December 15, 2034 | |
| Trade Date: | September 26, 2024 | |
| Settlement Date***: | September 30, 2024 (T+2) | |
| Interest Payment Dates: | Semi-annually on June 15 and December 15 of each year, beginning on December 15, 2024 | |
| Coupon: | 5.300% | |
| Benchmark Treasury: | 3.875% due August 15, 2034 | |
| Spread to Benchmark Treasury: | UST + 92 bps | |
| Benchmark Treasury Price / Yield: | 100-21 / 3.794% | |
| Re-Offer Yield: | 4.714% | |
| Denominations: | $2,000 and integral multiples of $1,000 in excess thereof | |
| Ranking: | Senior Unsecured | |
| Par Call Date: | September 15, 2034 | |
| Make-Whole Call: | UST + 15 bps | |
| CUSIP: | 59156RCN6 | |
| ISIN: | US59156RCN61 | |
| Joint Book-Running Managers: | Morgan Stanley & Co. LLC
BofA Securities, Inc.
Wells Fargo Securities, LLC | |
| ** | Net Proceeds are net of gross underwriting discount and prior to expenses. |
| *** | It is expected that delivery of the Notes will be made on or about September 30, 2024, which will be the second business day (T+2) following the date hereof. Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day (T+1), unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes more than one business day prior to the scheduled settlement date will be required, by virtue of the fact that the Notes will initially settle in T+2, to specify an alternative settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade the Notes more than one business day prior to the scheduled settlement date should consult their own advisors. |
The Issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in this offering will arrange to send you the prospectus if you request it by calling Morgan Stanley & Co. LLC at ###-###-####, BofA Securities, Inc. at ###-###-#### or Wells Fargo Securities, LLC at ###-###-####.
Schedule II - 2
SCHEDULE III
TO PRICING AGREEMENT
Underwriters’ Purchase Price of the $250,000,000 5.300% Senior Notes due 2034: 104.161% of the principal amount thereof
Closing Date: September 30, 2024
Addresses for Notices, etc. to the Representatives:
c/o Morgan Stanley & Co. LLC
1585 Broadway, 29th Floor
New York, New York 10036
United States of America
c/o BofA Securities, Inc.
One Bryant Park
New York, New York 10036
United States of America
c/o Wells Fargo Securities, LLC
550 South Tryon Street, 5th Floor
Charlotte, North Carolina 28202
Schedule III - 1
